S&P 500   4,580.26 (+0.63%)
DOW   35,678.11 (+0.53%)
QQQ   381.79 (+0.47%)
AAPL   150.80 (+1.31%)
MSFT   321.82 (-0.42%)
FB   310.14 (-0.67%)
GOOGL   2,924.52 (+0.01%)
TSLA   1,069.99 (+3.10%)
AMZN   3,390.75 (-0.05%)
NVDA   246.95 (+1.00%)
BABA   167.67 (-0.92%)
NIO   39.80 (+1.25%)
CGC   12.85 (+0.55%)
GE   103.42 (-0.41%)
AMD   121.30 (-0.80%)
MU   69.46 (+1.79%)
T   25.43 (+1.48%)
F   17.28 (+11.41%)
ACB   6.91 (+1.02%)
DIS   169.70 (+0.09%)
PFE   43.46 (+1.14%)
BA   205.50 (-0.54%)
AMC   35.25 (+1.41%)
S&P 500   4,580.26 (+0.63%)
DOW   35,678.11 (+0.53%)
QQQ   381.79 (+0.47%)
AAPL   150.80 (+1.31%)
MSFT   321.82 (-0.42%)
FB   310.14 (-0.67%)
GOOGL   2,924.52 (+0.01%)
TSLA   1,069.99 (+3.10%)
AMZN   3,390.75 (-0.05%)
NVDA   246.95 (+1.00%)
BABA   167.67 (-0.92%)
NIO   39.80 (+1.25%)
CGC   12.85 (+0.55%)
GE   103.42 (-0.41%)
AMD   121.30 (-0.80%)
MU   69.46 (+1.79%)
T   25.43 (+1.48%)
F   17.28 (+11.41%)
ACB   6.91 (+1.02%)
DIS   169.70 (+0.09%)
PFE   43.46 (+1.14%)
BA   205.50 (-0.54%)
AMC   35.25 (+1.41%)
S&P 500   4,580.26 (+0.63%)
DOW   35,678.11 (+0.53%)
QQQ   381.79 (+0.47%)
AAPL   150.80 (+1.31%)
MSFT   321.82 (-0.42%)
FB   310.14 (-0.67%)
GOOGL   2,924.52 (+0.01%)
TSLA   1,069.99 (+3.10%)
AMZN   3,390.75 (-0.05%)
NVDA   246.95 (+1.00%)
BABA   167.67 (-0.92%)
NIO   39.80 (+1.25%)
CGC   12.85 (+0.55%)
GE   103.42 (-0.41%)
AMD   121.30 (-0.80%)
MU   69.46 (+1.79%)
T   25.43 (+1.48%)
F   17.28 (+11.41%)
ACB   6.91 (+1.02%)
DIS   169.70 (+0.09%)
PFE   43.46 (+1.14%)
BA   205.50 (-0.54%)
AMC   35.25 (+1.41%)
S&P 500   4,580.26 (+0.63%)
DOW   35,678.11 (+0.53%)
QQQ   381.79 (+0.47%)
AAPL   150.80 (+1.31%)
MSFT   321.82 (-0.42%)
FB   310.14 (-0.67%)
GOOGL   2,924.52 (+0.01%)
TSLA   1,069.99 (+3.10%)
AMZN   3,390.75 (-0.05%)
NVDA   246.95 (+1.00%)
BABA   167.67 (-0.92%)
NIO   39.80 (+1.25%)
CGC   12.85 (+0.55%)
GE   103.42 (-0.41%)
AMD   121.30 (-0.80%)
MU   69.46 (+1.79%)
T   25.43 (+1.48%)
F   17.28 (+11.41%)
ACB   6.91 (+1.02%)
DIS   169.70 (+0.09%)
PFE   43.46 (+1.14%)
BA   205.50 (-0.54%)
AMC   35.25 (+1.41%)
NASDAQ:VERA

Vera Therapeutics Stock Forecast, Price & News

$17.17
-1.51 (-8.08 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.01
$18.76
50-Day Range
$14.25
$30.60
52-Week Range
$11.30
$33.45
Volume
18,650 shs
Average Volume
51,773 shs
Market Capitalization
$360.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive VERA News and Ratings via Email

Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Vera Therapeutics

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VERA
Employees
19
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$360.05 million
Next Earnings Date
11/15/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.86 out of 5 stars

Medical Sector

603rd out of 1,372 stocks

Pharmaceutical Preparations Industry

286th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Vera Therapeutics (NASDAQ:VERA) Frequently Asked Questions

Is Vera Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vera Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Vera Therapeutics stock.
View analyst ratings for Vera Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Vera Therapeutics?

Wall Street analysts have given Vera Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vera Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Vera Therapeutics?

Vera Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 23,300 shares, an increase of 651.6% from the August 31st total of 3,100 shares. Based on an average daily trading volume, of 56,600 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.3% of the company's stock are short sold.
View Vera Therapeutics' Short Interest
.

When is Vera Therapeutics' next earnings date?

Vera Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Vera Therapeutics
.

How were Vera Therapeutics' earnings last quarter?

Vera Therapeutics, Inc. (NASDAQ:VERA) posted its quarterly earnings data on Monday, August, 16th. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.06.
View Vera Therapeutics' earnings history
.

What price target have analysts set for VERA?

3 equities research analysts have issued 1 year price targets for Vera Therapeutics' shares. Their forecasts range from $24.00 to $24.00. On average, they expect Vera Therapeutics' stock price to reach $24.00 in the next year. This suggests a possible upside of 39.8% from the stock's current price.
View analysts' price targets for Vera Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Vera Therapeutics' key executives?

Vera Therapeutics' management team includes the following people:
  • Dr. Marshall Fordyce M.D., Founder, Pres, CEO & Director (Age 47, Pay $468k)
  • Mr. Jonathan R. Wolter, Chief Financial Officer (Age 71, Pay $246.36k)
  • Mr. Joseph R. Young, Sr. VP of Fin. (Age 49)
  • Dr. Joanne Curley Ph.D., Chief Devel. Officer (Age 52, Pay $448.75k)
  • Dr. Tad Thomas Ph.D., Sr. VP and Head of Product Devel. & Manufacturing (Age 61)
  • Mr. Tom Doan, Sr. VP of Devel. Operations (Age 49)
  • Ms. Lauren Frenz, Chief Bus. Officer (Age 36)
  • Dr. Celia Lin M.D., Chief Medical Officer (Age 46)

When did Vera Therapeutics IPO?

(VERA) raised $66 million in an initial public offering on Friday, May 14th 2021. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI acted as the underwriters for the IPO.

What is Vera Therapeutics' stock symbol?

Vera Therapeutics trades on the NASDAQ under the ticker symbol "VERA."

When does the company's lock-up period expire?

Vera Therapeutics' lock-up period expires on Wednesday, November 10th. Vera Therapeutics had issued 4,350,000 shares in its public offering on May 14th. The total size of the offering was $47,850,000 based on an initial share price of $11.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are Vera Therapeutics' major shareholders?

Vera Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Strs Ohio (0.01%).
View institutional ownership trends for Vera Therapeutics
.

Which institutional investors are buying Vera Therapeutics stock?

VERA stock was purchased by a variety of institutional investors in the last quarter, including Strs Ohio.
View insider buying and selling activity for Vera Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Vera Therapeutics?

Shares of VERA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vera Therapeutics' stock price today?

One share of VERA stock can currently be purchased for approximately $17.17.

How much money does Vera Therapeutics make?

Vera Therapeutics has a market capitalization of $360.05 million.

How many employees does Vera Therapeutics have?

Vera Therapeutics employs 19 workers across the globe.

What is Vera Therapeutics' official website?

The official website for Vera Therapeutics is veratx.com.

How can I contact Vera Therapeutics?

The company can be reached via phone at 650-770-0077 or via email at [email protected].


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.